Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
UPB
STRONG SELLUpstream Bio, Inc. · Healthcare · United States · $349M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Upstream Bio, Inc. is a biotechnology company focused on discovering and developing novel therapeutics for inflammatory and immunological diseases. The company's competitive moat is built upon its proprietary drug candidates, designed to target specific pathways involved in various immune-mediated conditions, addressing critical unmet needs in these therapeutic areas. Upstream Bio is an emerging biopharmaceutical firm committed to advancing immunology research.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2M | 2.4M | 2.4M | 2.9M | 33.0% | 3.3M | 2.0M | 1.7M | -23.9% |
| EPS | -0.66 | -1.05 | -1.17 | -2.64 | — | -2.90 | -2.84 | -2.89 | — |
| Shares | 51.3M | 51.3M | 53.6M | 54.2M | +5.6% | 54.4M | — | — | — |
| Debt | 94.0K | 45.0K | 1.8M | 1.3M | 138.1% | 1.1M | — | — | — |
| Equity | -106.2M | -123.1M | 469.9M | 339.8M | -27.7% | — | — | — | — |
| Op CF | -19.0M | -37.9M | -59.2M | -133.3M | — | -140.0M | — | — | — |
| Inv CF | -82.0K | -82.8M | -59.5M | -93.5M | — | — | — | — | — |
| Fin CF | 10.0M | 129.6M | 418.9M | 2.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of UPB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| UPB | Upstream Bio, Inc.(you) | $349M | 8 | STRONG SELL |
| INDP | Indaptus Therapeutics, Inc. | $348M | 8 | STRONG SELL |
| CMPX | Compass Therapeutics, Inc. | $373M | 7 | STRONG SELL |
| EDIT | Editas Medicine, Inc. | $399M | 8 | STRONG SELL |
| EVMN | Evommune, Inc. | $409M | 7 | STRONG SELL |
| DMAC | DiaMedica Therapeutics Inc. | $363M | 12 | STRONG SELL |
| FHTX | Foghorn Therapeutics Inc. | $285M | 6 | STRONG SELL |
| LXEO | Lexeo Therapeutics, Inc. | $366M | 13 | STRONG SELL |
| PROK | ProKidney Corp. | $453M | 7 | STRONG SELL |
| LCTX | Lineage Cell Therapeutics, Inc. | $257M | 8 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%